CTOs on the Move

Arcadia Health Care

www.arcadiahomecare.com

 
Arcadia Health Care is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Matheny Medical and Educational Center

Matheny Medical and Educational Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Peapack, NJ. To find more information about Matheny Medical and Educational Center, please visit www.matheny.org

Sebastian International Inc

Sebastian International Inc is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Systems Xcellence

Systems Xcellence, Inc is a Milton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dickinson Mental Health Center

Dickinson Mental Health Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Dickinson Mental Health Center is based in Ridgway, PA. You can find more information on Dickinson Mental Health Center at www.dmhc.org

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.